{
    "clinical_study": {
        "@rank": "87204", 
        "arm_group": [
            {
                "arm_group_label": "PF-05089771 Oral Dispersion fasted", 
                "arm_group_type": "Experimental", 
                "description": "Oral dispersion TS formulation- fasted"
            }, 
            {
                "arm_group_label": "PF-05089771 TS formulation fasted", 
                "arm_group_type": "Experimental", 
                "description": "Capsules TS formulation- fasted"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to estimate the relative bioavailability and food\n      effect of a PF-05089771 capsule."
        }, 
        "brief_title": "A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or non-childbearing potential female subjects between the ages of 18\n             and 55 years\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal,endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing).\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy).\n\n          -  A positive urine drug screen.\n\n          -  History of regular alcohol consumption exceeding 14 drinks/week for females or 21\n             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of\n             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.\n\n          -  Treatment with an investigational drug within 60 days (or as determined by the local\n             requirement, whichever is longer) or 5 half-lives preceding the first dose of study\n             medication.\n\n          -  Screening supine blood pressure \u2265140 mm Hg (systolic) or \u226590 mm Hg (diastolic), on a\n             single measurement (confirmed by a single repeat, if necessary) following at least 5\n             minutes of rest 7. Single 12-lead ECG demonstrating QTc >450 msec or a QRS interval\n             >120 mseca at screening. If QTc exceeds 450 msec, or QRS exceeds >120 mseca the ECG\n             should be repeated two more times and the average of the three QTc or QRS values\n             should be used to determine the subject's eligibility."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690351", 
            "org_study_id": "B3291015"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05089771 Oral Dispersion fasted", 
                "description": "Oral dispersion TS formulation- fasted", 
                "intervention_name": "PF-05089771", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-05089771 TS formulation fasted", 
                "description": "Capsules TS formulation- fasted", 
                "intervention_name": "PF-05089771", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 10, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3291015&StudyName=A%20Study%20Comparing%20PF-05089771%20TS%20Capsule%20To%20PF-05089771%20TS%20Oral%20Dispersion%20In%20The%20Fasted%20State%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bruxelles", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open Label, Single Dose, Bioavailability Study In Healthy Volunteers Comparing PF-05089771 TS Oral Dispersion To PF-05089771 TS Capsule", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Belgian Health Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum concentration (Cmax) for PF-05089771 in plasma (measured in ng/mL)", 
                "safety_issue": "No", 
                "time_frame": "days 1-2"
            }, 
            {
                "measure": "AUClast = Area under the curve from the time of dosing to the last data point taken (ng.hr/mL)", 
                "safety_issue": "No", 
                "time_frame": "days 1-2"
            }, 
            {
                "measure": "AUCinf = Area under the curve from the time of dosing extrapolated to infinity (ng.hr/mL)", 
                "safety_issue": "No", 
                "time_frame": "days 1-2"
            }, 
            {
                "measure": "Tmax = Time of maximum concentration of PF-05089771 in plasma (hr)", 
                "safety_issue": "No", 
                "time_frame": "days 1-2"
            }, 
            {
                "measure": "t\u00bd = Elimination half life of PF-05089771 (hr)", 
                "safety_issue": "No", 
                "time_frame": "days 1-2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690351"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "evaluation of safety clinical laboratory tests, vital signs, ECGs, physical examinations and adverse event monitoring.", 
            "safety_issue": "Yes", 
            "time_frame": "days 1-2"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}